This discussion with Stanford Biodesign director and co-founder Josh Makower highlights a recent Stanford report that found the median time for initial Medicare coverage of Breakthrough Devices is nearly six years. Here we discuss how this data, much like information from previous Stanford reports, can help drive change at CMS through the current TCET debate.Read Article
Stephen Levin has spent nearly 25 years covering the life sciences industry, writing and speaking primarily on medical technology worldwide. Before Levin and his partner, David Cassak, launched Innovation In Medtech, LLC, the parent company of MEDTECH STRATEGIST and MARKET PATHWAYS, along with international conferences, Levin formerly was Editor-in-Chief/Medical Devices at Elsevier Business Intelligence (EBI). At EBI, he directed the editorial coverage for the company’s medtech publications, including IN VIVO, START-UP, MEDTECH INSIGHT, THE GRAY SHEET, and THE SILVER SHEET, along with the content for the Investment In Innovation (IN3) series of medical device partnering conferences.
Prior to joining Windhover, Levin was Senior Counsel to the US Senate Permanent Subcommittee on Investigations, where he directed Senate investigations into a wide variety of areas including health care fraud and abuse, international organized crime, and corruption in federal contracting programs, while also participating in other Senate investigations, including the Whitewater inquiry. Before joining the Subcommittee, Levin was an enforcement and regulatory attorney in the Federal Election Commission’s Office of General Counsel, and also worked at the US Department of Justice. He was formerly an Editor of HEALTH INDUSTRY TODAY, a leading publication in the health care distribution industry.